急性二甲双胍激发后血浆浓度的遗传与临床相关因素
SUGAR-MGH 研究在 745 名完成标准化急性二甲双胍激发的多祖先参与者中评估血浆二甲双胍浓度的临床与遗传因素。结果显示年龄较大、eGFR 较低和 BMI 较低与浓度较高相关,非洲祖先与浓度较低相关,GWAS 发现四个非洲祖先特异性变异与浓度较高显著相关。
要点
- 年龄较大、eGFR 较低、BMI 较低与二甲双胍浓度较高相关。
- 非洲祖先与二甲双胍浓度较低相关。
- GWAS 发现四个非洲祖先特异性变异与浓度较高显著相关。
核心结论
- 年龄较大、eGFR 较低和 BMI 较低与急性二甲双胍激发后血浆二甲双胍浓度较高独立相关。
- 非洲祖先与血浆二甲双胍浓度较低相关。
- GWAS 识别出四个非洲祖先特异性变异与较高二甲双胍浓度显著相关。
- 与二甲双胍浓度相关的顶级变异未与激发后血糖反应终点相关。
- 既往报道的二甲双胍转运体变异与二甲双胍浓度无显著关联。
研究设计与样本
- SUGAR-MGH 研究纳入 745 名完成标准化急性二甲双胍激发的多祖先参与者,评估临床与遗传因素与血浆二甲双胍浓度的关联。
主要发现
- 年龄较大与较高二甲双胍浓度相关(β=2.5 ng/mL 每岁,p=0.02)。
- eGFR 较低与较高二甲双胍浓度相关(β=-3.5 ng/mL 每 ml/min/1.73m2,p=4.5×10-4)。
- BMI 较低与较高二甲双胍浓度相关(β=-7.3 ng/mL 每 kg/m2,p=1.3×10-4)。
- 非洲祖先与较低二甲双胍浓度相关(β=-72.6 ng/mL,p=0.036)。
- GWAS 发现四个非洲祖先特异性变异与较高二甲双胍浓度显著相关(p<5×10-8)。
临床怎么用
- 临床解读二甲双胍血浆浓度时需考虑年龄、eGFR 和 BMI。
- 非洲祖先个体的二甲双胍浓度可能较低,需关注 ancestry 对药代动力学的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The glycemic response to metformin is highly variable, yet the genetic determinants of metformin pharmacokinetics remain poorly characterized. In the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH), an ancestrally diverse cohort, we evaluated clinical and genetic factors associated with plasma metformin concentrations. Plasma metformin concentrations were measured in 745 participants who completed a standardized acute metformin challenge in SUGAR-MGH. Higher metformin concentrations were associated with older age (β=2.5 ng/mL per year, p = 0.02), lower eGFR (β=-3.5 ng/mL per ml/min/1.73m2, p = 4.5 × 10-4), and lower BMI (β=-7.3 ng/mL per kg/m2, p = 1.3 × 10-4). African ancestry was associated with lower metformin concentrations compared to European ancestry (β=-72.6 ng/mL, p = 0.036). A genome-wide association study (GWAS) identified four African ancestry-specific genetic variants significantly associated with higher metformin concentrations (p < 5 × 10-8) as well as several suggestive loci near genes implicated in glucose metabolism, including USP36 and DGKB. Top variants associated with metformin concentration were not associated with glycemic response endpoints following the metformin challenge, including fasting glucose at Visit 2, change in HOMA-IR, and change in fasting insulin between visits. Previously reported metformin transporter variants showed no significant associations with metformin concentration. These findings represent the first GWAS of metformin plasma concentrations and provide a novel resource for future studies of metformin pharmacogenetics.
引用
- Kuo B, Nam S, Kaur V, et al. Genetic and Clinical Factors Associated With Metformin Plasma Concentrations Following an Acute Metformin Challenge. J Clin Endocrinol Metab. 2026. PMID: 42394225. doi:10.1210/clinem/dgag262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。